Angiotensin-Converting Enzyme Inhibitors
"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
Descriptor ID |
D000806
|
MeSH Number(s) |
D27.505.519.389.745.085
|
Concept/Terms |
Angiotensin-Converting Enzyme Inhibitors- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin Converting Enzyme Inhibitors
- Inhibitors, Kininase II
- Kininase II Antagonists
- Kininase II Inhibitors
- Angiotensin I-Converting Enzyme Inhibitors
- Angiotensin I Converting Enzyme Inhibitors
- Antagonists, Angiotensin-Converting Enzyme
- Antagonists, Angiotensin Converting Enzyme
- Antagonists, Kininase II
- Inhibitors, ACE
- ACE Inhibitors
- Inhibitors, Angiotensin-Converting Enzyme
- Enzyme Inhibitors, Angiotensin-Converting
- Inhibitors, Angiotensin Converting Enzyme
- Angiotensin-Converting Enzyme Antagonists
- Angiotensin Converting Enzyme Antagonists
- Enzyme Antagonists, Angiotensin-Converting
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".
This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 1 | 1 | 2 |
2003 | 0 | 1 | 1 |
2004 | 1 | 0 | 1 |
2005 | 0 | 1 | 1 |
2006 | 1 | 1 | 2 |
2008 | 1 | 1 | 2 |
2009 | 1 | 1 | 2 |
2010 | 3 | 2 | 5 |
2011 | 2 | 1 | 3 |
2012 | 2 | 2 | 4 |
2013 | 1 | 1 | 2 |
2014 | 0 | 1 | 1 |
2015 | 1 | 5 | 6 |
2016 | 0 | 2 | 2 |
2017 | 4 | 0 | 4 |
2018 | 1 | 1 | 2 |
2019 | 2 | 3 | 5 |
2020 | 4 | 5 | 9 |
2021 | 2 | 3 | 5 |
2022 | 1 | 3 | 4 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.
-
National Trends in Hospital Performance in Guideline-Recommended Pharmacologic Treatment for Heart Failure at Discharge. JACC Heart Fail. 2024 Jun; 12(6):1059-1070.
-
Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes. Am J Nephrol. 2023; 54(7-8):258-267.
-
Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity. Am J Med. 2022 12; 135(12):1468-1477.
-
Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25?000 Medicare beneficiaries. Eur J Heart Fail. 2022 Sep; 24(9):1506-1515.
-
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. Am Heart J. 2022 May; 247:76-89.
-
Laboratory monitoring to reduce adverse drug-related events: a mixed methods study. J Manag Care Spec Pharm. 2022 Jan; 28(1):16-25.
-
Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease. Pharmacotherapy. 2021 12; 41(12):998-1008.
-
Physician adjudication of angioedema diagnosis codes in a population of patients with heart failure prescribed angiotensin-converting enzyme inhibitor therapy. Pharmacoepidemiol Drug Saf. 2021 12; 30(12):1630-1634.
-
Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021 04 27; 77(16):1961-1973.
-
Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study. Am J Hypertens. 2021 04 20; 34(4):339-347.